Liên kết phospholipid của kháng thể kháng phospholipid và protein chống đông thai nghén

Harris EN, Gharavi AE, Boey ML,et al. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2:1211–1214, 1983 Harris EN, Gharavi AE, Hughes GRV: Antiphospholipid antibodies. Clin Rheum Dis 11:591–609, 1985 Hughes GRV, Harris EN, Gharavi AE: The anticardiolipin syndrome. J Rheum 13:486–489, 1986 Alarcon-Segovia D, Deleze M, Oria CV,et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. Medicine 68:353–365, 1989 Mackworth-Young CG, Loizou S, Walport MJ: Primary antiphospholipid syndrome: Features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 48:363–367, 1989 Lockshin MD, Druzin ML, Goei S,et al. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 313:152–156, 1985 Branch DW, Scott JR, Kochenour,et al. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 313:1322–1326, 1985 Lubbe WF, Liggins GC: Lupus anticoagulant and pregnancy. Am J Obstet Gynecol 153:322–327, 1985 DeWolf F, Carreras LO, Moerman P,et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 142:829–834, 1982 Cines DB, Lyss AP, Reeber M,et al. Presence of complement-fixing antiendothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 73:611–625, 1984 Vismara A, Meroni PL, Tincani A,et al. Relationship between anticardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 74:247–253, 1988 Carreras LO, Vermylen JG: “Lupus” anticoagulant and thrombosis—possible role of inhibition of prostacyclin formation. Thromb Haem 42:38–40, 1982 Rustin MHA, Bull HA, Machin SJ,et al. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 90:744–748, 1988 Cariou R, Tobelem G, Bellucci S,et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—inhibition of thrombomodulin dependent protein C activation. Thromb Haem 60:54–58, 1988 Angeles-Cano E, Sultan Y, Clauvel JP: Predisposing factors to thrombosis in systemic lupus erythematosus: Possible relation to endothelial cell damage. J Lab Clin Med 94:312–323, 1979 Francis RB, McGehee WG, Feinstein DI: Endothelialdependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haem 39:412–414, 1988 Moreb J, Kitchens CS: Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: Report of 2 cases. Am J Med 87:207–210, 1989 Cosgriff TM, Martin BA: Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arth Rheum 24:94–96, 1981 Crompton MR, Moss SE, Crumpton MJ: Diversity in the lipocortin/calpactin family. Cell 55:1–3, 1988 Tait JF, Sakata M, McMullen B,et al. Placental anticoagulant protein proteins: Isolation and comparative characterization of four members of the lipocortin family. Biochemistry 27:6268–6276, 1988 Reutelingsperger CPM, Hornstra G, Henker HC: Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 151:625–629, 1989 Iwasaki A, Suda M, Nakao H,et al. Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: A new lipocortin-like protein. J Biochem 102:1261–1273, 1987 Funakoshi T, Heimark RL, Hendrickson LE,et al. Human placental anticoagulant protein: isolation and characterization. Biochemistry 26:5572–5578, 1987 Flaherty MJ, West S, Heimark R: Placental anticoagulant protein I: Measurement in extracellular fluids and cells of the hemostatic system. J Lab Clin Med 115:174–179, 1990 Tait JF, Gibson D, Kujikawa K: Phospholipid binding properties of human placental anticoagulant protein I, a member of the lipocortin family. J Biol Chem 264:7944–7949, 1989 Reutelingsperger CPM, Kop JMM, Hornstra G,et al. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation. Eur J Biochem 1973:171–178, 1988 Kondo S, Naguchi M, Funakoshi T,et al. Inhibition of human factor VIIa—tissue factor activity by placental anticoagulant protein. Thromb Res 48:449–459, 1987 Triplett DA, Brandt JT, Musgrave KA,et al. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 259:550–554, 1988 Rosove MH, Brewer PMC, Runge A,et al. Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids. Am J Hematol 32:148–149, 1989 Violi F, Valesini G, Ferro D,et al. Anticoagulant activity of anticardiolipin antibodies. Thromb Res 44:543–547, 1986 McNeil HP, Chesterman CN, Krilis SA: Binding specificity of lupus anticoagulants and anticardiolipin antibodies. Throm Res 52:609–619, 1988 Derksen RH, Hasselaar P, Blokzijl L,et al. Coagulation screen is more specific than the anticardiolipin ELISA in defining a throbotic subset of lupus patients. Ann Rheum Dis 47:364–371, 1988 Petri M, Rheinschmidt M, Whiting O'Keefe Q,et al. The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolpin antibody. Ann Intern Med 106:524–531, 1987 Lockshin MD, Qamar T, Druzin ML,et al. Comparison of antibody to cardiolipin and aPTT as predictors of fetal death in pregnant patients with SLE. J Rheum 14:259–262, 1987 Alving BM, Barr CF, Tang DB: Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin time. Am J Med 88:112–116, 1990 Thiagarajan P, Shapiro S, DeMarco L: Monoclaonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity: Mechanism of a lupus anticoagulant. J Clin Invest 66:397–405, 1980 Pengo V, Thiagarajan P, Shapiro S: Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70:69–76, 1987 Galli M, Beguin S, Lindhout T,et al. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Br J Haematol 72:549–555, 1989 Calandri C, Rand JH: Anticardiolipin antibodies block placental anticoagulant protein activity. Clin Res 38:427A, 1990 (abstr) Exner T: Comparison of two simple tests for the lupus anticoagulant. AJCP 83:215–218, 1985 Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72:248–254, 1976 Weber K, Osborne M: The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 244:4406–4412, 1969 Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350–4354, 1979 Avrameas S, Ternynck T: The cross-linking of proteins with glutaraldehyde and its use for the preparation of immunoabsorbents. Immunochemistry 6:53–66, 1969 Gharavi AE, Harris EN, Asherson RA,et al. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Ann Rheum Dis 46:1–6, 1987 Cullis PR, Hope MJ, de Kruijff,et al. Structural properties and functional roles of phospholipids in biological membranes. InPhospholipids and Cellular Regulation, JF Kuo (ed). Boca Raton, FL, CRC Press, 1985, pp 1–60 Green FA, Costello PB: Divalent cation effects on the binding of human anti-phospholipid antibodies. Biochim Biophys Acta 896:47–51, 1987 Geisow MJ: Common domain structure of Ca2+ and lipid binding proteins. FEBS Lett 203:99–103, 1986 Davidson FF, Dennis EA, Powell M,et al. Inhibition of phospholipase A2 by lipocor and calpactins: An effect of binding to substrate phopholipids. J Biol Chem 262:1698–1705, 1987 Ahn NG, Teller DC, Bienkowski NJ,et al. Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. J Biol Chem 263:18657–18663, 1988 Huang KS, Wallner BP, Mattaliano RJ: Two human 35 kd inhibitors of phospholipase A2 are related to substrates of pp 60v-src and of the epidermal growth factor receptor/kinase. Cell 46:191–199, 1986 Funakoshi T, Hendrickson LE, McMullen BA,et al. Primary structure of human placental anticoagulant protein. Biochemistry 26:8087–8092, 1987 Maurer-Fogy I, Reutelingsperger CPM, Pieters J,et al. Cloning and expression of cDNA for human vascular anticoagulant, a Ca2+-dependent phospholipid binding protein. Eur J Biochem 174:585–592, 1988 Romisch J, Schorlemmer U, Fickenscher K,et al. Anticoagulant properties of placenta protein 4 (annexin V). Thrombos Res 60:355–366, 1990 Exner T, Richard KA, Kronenberg H: A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 40:143–151, 1978 Exner T, Sahman N, Trudinger B: Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Comm 155:1001–1007, 1988 McNeil HP, Chesterman CN, Krilis SA: Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 73:506–513, 1989 Harris EN, Gharavi AE, Tincani A,et al. Affinity purified anticardiolipin and anti-DNA antibodies. J Clin Lab Immunol 17:155–162, 1985 Rauch J, Tannenbaum M, Tannenbaum H: Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 261:9672–9677, 1986 Galli M, Comfurius P, Maasen C,et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544–1547, 1990 McNeil HP, Simpson RJ, Chesterman CN, Krillis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120–4124, 1990 Sammaritano LR, Lockshin MD, Gharavi AE: Antiphospholipid antibodies differ in aPL cofactor requirement (Submitted for publication)